Related Experiment Video
Updated: Jul 7, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
CYP4F2 genetic variant alters required warfarin dose
Michael D Caldwell1, Tarif Awad, Julie A Johnson
1Department of Surgery, Marshfield Clinic, Marshfield, WI, USA.
Blood
|February 6, 2008
Summary
A newly identified genetic variant in CYP4F2 influences warfarin dose requirements. This finding helps explain variability in warfarin sensitivity and may improve patient treatment.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Genetics
Background:
- Warfarin is a critical anticoagulant, but its use is limited by adverse events and dose variability.
- Genetic factors significantly impact individual warfarin response, necessitating frequent monitoring.
- Existing research highlights polymorphisms in warfarin metabolism and sensitivity genes.
Purpose of the Study:
- To identify novel genetic variants affecting warfarin dose requirements.
- To investigate the role of additional drug-metabolizing enzymes and transporters in warfarin pharmacogenetics.
- To characterize the clinical significance of identified genetic variations on warfarin therapy.
Main Methods:
- Screening of DNA variants using the Affymetrix drug-metabolizing enzymes and transporters panel.
- Association analysis of genetic variants with stable warfarin dose in three independent white cohorts.
- Statistical evaluation of the impact of genetic variation on daily warfarin requirements.
Main Results:
- A novel DNA variant, rs2108622 (V433M) in cytochrome P450 4F2 (CYP4F2), was identified.
- This CYP4F2 variant was significantly associated with warfarin dose requirements across diverse US white populations.
- Carriers of different rs2108622 genotypes (CC vs. TT) exhibited an approximate 1 mg/day difference in warfarin dose.
Conclusions:
- Genetic variation in CYP4F2 influences warfarin requirements, demonstrating a clinically relevant effect.
- The rs2108622 variant contributes to interindividual variability in warfarin dosing.
- This discovery may aid in optimizing warfarin therapy through genetic-guided dosing strategies.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...